Previous 10 | Next 10 |
Gainers: Revelation Biosciences REVB +29%. Mainz Biomed MYNZ +9%. Relmada Therapeutics (NASDAQ:RLMD) +9%. Panbela Therapeutics (NASDAQ:PBLA) +7%. Pyxis Oncology (NASDAQ:PYXS) +4%. Losers: Kodiak Sciences KOD -78%. Ocugen OCGN -20%. R...
Panbela Therapeutics (NASDAQ:PBLA) is rising 7.9% premarket Tuesday after firm has agreed to acquire Cancer Prevention Pharmaceuticals (CPP), a private clinical stage company developing therapeutics to reduce the risk and recurrence of cancer and rare diseases, for a combination of ...
Creates late-stage, diversified pipeline that uses a multi-targeted approach to reset dysregulated biology to address considerable unmet needs Combined pipeline extends from pre-clinical to registration studies, with near-term clinical and regulatory milestones Acquired lead ass...
MINNEAPOLIS, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced the initiation of the company’s global Phase 2 cl...
Interim data presented in poster reflects median overall survival of 12.0 months, not yet final, and an objective response rate of 48%, both greater than histor ical rates reported for standard of care MINNEAPOLIS, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Panb...
MINNEAPOLIS, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with cancer, today announced positive preclinical data supporting the activity of SBP-101 in ovarian ca...
The following slide deck was published by Panbela Therapeutics Inc. in conjunction with this event. For further details see: Panbela Therapeutics (PBLA) Investor Presentation - Slideshow
MINNEAPOLIS, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc . (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today announced that an abstract for SBP-101, a proprietary polyamine anal...
Panbela Therapeutics Inc. (PBLA) Q3 2021 Earnings Conference Call November 10, 2021 04:30 PM ET Company Participants James Carbonara - Investor Relations Jennifer Simpson - Chief Executive Officer Sue Horvath - Chief Financial Officer Conference Call Participants Robin Garner - Craig-Hallum T...
Panbela Therapeutics (NASDAQ:PBLA): Q3 GAAP EPS of -$0.16. Cash and cash equivalents was $14.1M Press Release For further details see: Panbela Therapeutics reports Q3 results
News, Short Squeeze, Breakout and More Instantly...
Panbela Therapeutics Inc Com Company Name:
PBLA Stock Symbol:
NASDAQ Market:
Panbela Therapeutics Inc Com Website:
DSMB Recommends Continuation without Modification for Third Time Safety Review Included 395 Patients Interim Survival Analysis Still Expected Early 2025 given Lower-Than-Expected Event Rate Low Event Rate Suggests Potential for Prolonged Survival Rapid Enrollment P...
MINNEAPOLIS, June 10, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc . (OTCQB: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announces an oral presentation at the Digestive Disease Week (DDW) conference,...
MINNEAPOLIS, May 15, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the q...